Weekly Roundup 10 Nov 2023
Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs
…lead product candidate in alpha-1 antitrypsin deficiency (AATD) through a clinical milestone, progression of additional product candidates from the pipeline into the clinic, and demonstrating applicability of the RNA editing…